Table_2_Immune Checkpoints OX40 and OX40L in Small-Cell Lung Cancer: Predict Prognosis and Modulate Immune Microenvironment.docx

BackgroundOX40 and OX40 ligand (OX40L), as essential immune checkpoint (IC) modulators, are highly correlated with cancer immunity regulation as well as tumor microenvironment (TME). Immunotherapy showed outstanding advantages in small-cell lung cancer (SCLC) therapy. However, functions and clinical significance of OX40 and OX40L in SCLC were not clear yet.Materials and MethodsSCLC samples of 143 patients were collected for immunohistochemistry (IHC) or whole-exome sequencing (WES). We comprehensively explored the expression and mutation of OX40/OX40L in SCLC, and systematically linked OX40/OX40L with TME.ResultsThe expression of OX40/OX40L on tumor cells and tumor-infiltrating lymphocytes (TILs) was found in the IHC cohort and verified in other cohorts with SCLC tissues and cell lines. The results showed co-expression patterns among OX40/OX40L, other ICs, and T-cell markers. The WES data suggested that OX40/OX40L mutation is rare in SCLC (

背景：OX40及其配体OX40L（OX40L）作为关键的免疫检查点（IC）调节因子，与癌症免疫调节及肿瘤微环境（TME）密切相关。免疫治疗在小细胞肺癌（SCLC）的治疗中展现出卓越的疗效。然而，OX40和OX40L在SCLC中的功能及其临床意义尚不明确。材料与方法：收集了143例SCLC患者的样本，用于免疫组织化学（IHC）或全外显子测序（WES）。我们全面探究了OX40/OX40L在SCLC中的表达和突变情况，并系统地将其与TME联系起来。结果：在IHC队列中发现了肿瘤细胞和肿瘤浸润淋巴细胞（TILs）上的OX40/OX40L表达，并在其他SCLC组织细胞系队列中得到验证。结果表明OX40/OX40L与其它免疫检查点和T细胞标记物存在共表达模式。全外显子测序数据表明，OX40/OX40L突变在SCLC中较为罕见（